Incyte Corporation's SEC filings document a Nasdaq-listed biopharmaceutical issuer with common stock trading under INCY and product franchises in hematology, oncology, and inflammation and autoimmunity. Form 8-K reports cover operating results, product sales trends for Jakafi and Opzelura, financial guidance, pipeline updates, and regulatory correspondence affecting drug applications.
Proxy and current-report filings also disclose board and executive changes, officer appointments, equity compensation, shareholder voting matters, executive pay, governance practices, and registered security information. These filings frame Incyte's capital structure, leadership oversight, commercial portfolio, clinical-development programs, and regulatory risks.
Vijay Iyengar filed a notice to sell 12743 shares of Incyte (INCY) common stock under Rule 144. The shares are to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services on NASDAQ, with an aggregate market value of 1388987.00.
The filing states that 196322703 shares of common stock were outstanding. The 12743 shares to be sold were acquired on 02/09/2026 via a stock option exercise paid in cash the same day. The notice also reports prior sales over the past three months, including 95811 shares sold on 01/06/2026 for gross proceeds of 9998255.70.
Incyte Corporation executive Michael James Morrissey reported a small share withholding related to equity compensation. On February 2, 2026, 185 shares of Incyte common stock were withheld at $102.67 per share to cover tax obligations from previously granted restricted stock units.
After this withholding, Morrissey beneficially owns 34,065 shares of Incyte common stock directly. This total includes 22,560 shares tied to previously reported restricted stock units and earned performance stock units that are not yet vested, reflecting ongoing equity-based compensation rather than an open-market sale.
Incyte Corporation executive Heeson Lee reported a routine tax-related share transaction. On 02/02/2026, 111 shares of Incyte common stock were withheld automatically at a price of $102.67 per share to satisfy tax obligations from settling previously granted restricted stock units.
After this withholding, Lee beneficially owned 38,041 shares of Incyte common stock directly. This total includes 33,496 shares that are issuable from earlier reported restricted stock units that have not yet vested, reflecting a significant portion of equity held in unvested awards.
Incyte Corporation executive Heeson Lee reported a stock-based compensation grant. On January 16, 2026, Lee received 8,911 shares of common stock, awarded in the form of restricted stock units (RSUs) at a price of $0 per share.
The RSUs will vest 25% each year over four years and can be settled only in shares of Incyte common stock on a one-for-one basis. After this grant, Lee beneficially owns 38,152 shares of common stock, including an aggregate of 35,078 shares underlying previously reported RSUs that have not yet vested.
Incyte Corporation reported a new stock option grant to a senior executive. President of R&D Pablo J. Cagnoni received an employee stock option to purchase 28,475 shares of Incyte common stock at an exercise price of $106.21 per share, effective January 16, 2026.
The option was granted at no cost to the executive and is held directly. Beginning January 16, 2026, the award becomes exercisable in 37 installments, with the first 25% vesting on July 15, 2026 and the remaining portion vesting monthly over the following three years. After this grant, Cagnoni beneficially owns 28,475 derivative securities in the form of these options.
Incyte Corporation executive Steven H. Stein, EVP & Chief Medical Officer, reported a new stock option grant. On January 16, 2026, he received an employee stock option to purchase 19,932 shares of Incyte common stock at an exercise price of $106.21 per share. These options begin to become exercisable in 37 installments starting January 16, 2026.
The vesting schedule provides that the first 25% of the options vest on July 15, 2026, with the remaining options vesting in monthly installments over the following three years. The option expires on January 15, 2036, giving a ten-year term from the grant date.
Incyte Corporation executive Issa Mohamed Khairie, EVP and Head of US Oncology, reported a new stock option grant. On January 16, 2026, he received an employee stock option giving the right to buy 14,237 shares of Incyte common stock at an exercise price of $106.21 per share, expiring on January 15, 2036. Following this grant, he beneficially owned 14,237 derivative securities directly.
The options begin to become exercisable in 37 installments starting January 16, 2026. The first 25% will vest on July 15, 2026, with the remaining portion vesting monthly over the next three years, tying the long-term incentive to continued service and performance.
Incyte Corporation executive Matteo Trotta, EVP and GM of Dermatology US, reported a grant of employee stock options on common stock. On January 16, 2026, he received 8,542 stock options with an exercise price of $106.21 per share and no cost for the option grant itself. These options expire on January 15, 2036.
Beginning January 16, 2026, the options become exercisable in 37 installments, with the first 25% vesting on July 15, 2026 and the remaining options vesting monthly over the following three years. After this grant, Trotta beneficially owns 8,542 derivative securities directly in the form of these options.
Incyte Corporation’s Principal Accounting Officer, Tray Thomas, reported receiving an employee stock option grant under the company’s equity plan. On January 16, 2026, Thomas was awarded options to purchase 2,425 shares of Incyte common stock at an exercise price of $106.21 per share.
According to the filing, these options begin to vest on January 16, 2026 in 37 installments. The first 25% of the grant vests on July 15, 2026, and the remaining options vest monthly over the following three years. All 2,425 derivative securities are held directly by the reporting officer.
Incyte Corporation executive Patrick A. Mayes, EVP & Chief Scientific Officer, reported a grant of 4,218 employee stock options on January 16, 2026. These options have an exercise price of $106.21 per share and give the right to buy Incyte common stock.
Beginning January 16, 2026, the options become exercisable in 37 installments, with the first 25% vesting on July 15, 2026 and the remaining portion vesting monthly over the following three years, and they expire on January 15, 2036. After this award, Mayes beneficially owns 4,218 derivative securities directly.